Document Detail


Biology and treatment of the 5q- syndrome.
MedLine Citation:
PMID:  21322779     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The 5q- syndrome is a unique subtype of myelodysplastic syndromes typified by a relatively indolent course and responsiveness to lenalidomide. Here, we review the salient biologic features of this disease. Hemizygous deletion of a segment of chromosome 5q is believed to be the disease-initiating event. Recent molecular techniques have isolated the common deleted region and characterized key candidate genes contributing to the disease phenotype. Gene-specific RNA interference strategies revealed that haplo-insufficiency for the RPS14 gene, which encodes a ribosomal protein, is a critical effector of the p53-dependent erythroid hypoplasia and apoptotic loss of erythroid precursors. Disease-specific sensitivity to lenalidomide results from the drug's inhibitory effect on two haplodeficient phosphatases, PP2Acα and CDC25c, which are coregulators of the G(2)/M checkpoint. Hyperphosphorylation of MDM2, as a result of inhibition of PP2A phosphatase activity, stabilizes MDM2, permitting p53 degradation and transition to G(2) arrest and clonal suppression. With the emerging data elucidating the pathogenesis of the 5q- syndrome and the success of clinical trials, a cohesive story connecting the biology and pharmacology associated with this subtype of myelodysplastic syndromes has emerged.
Authors:
Eric Padron; Rami Komrokji; Alan F List
Related Documents :
22200739 - Updated epidemiologic study of urolithiasis in turkey ii: role of metabolic syndrome co...
22005869 - Published evidence relevant to the diagnosis of impingement syndrome of the shoulder.
22190289 - Long-term follow-up of patients with postural tachycardia syndrome.
22022089 - Hennekam lymphangiectasia syndrome.
21961919 - Early menopause in mothers of children with down syndrome?
22178199 - Primary biliary cirrhosis and sjögren's syndrome: autoimmune epithelitis.
18379259 - Abdominal compartment syndrome: a concise clinical review.
7888369 - Livedo reticularis associated with hereditary protein c deficiency and recurrent thromb...
11441329 - Cocaine-induced torsades de pointes in idiopathic long q-t syndrome.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert review of hematology     Volume:  4     ISSN:  1747-4094     ISO Abbreviation:  Expert Rev Hematol     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-02-16     Completed Date:  2011-05-27     Revised Date:  2011-12-06    
Medline Journal Info:
Nlm Unique ID:  101485942     Medline TA:  Expert Rev Hematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  61-9     Citation Subset:  IM    
Affiliation:
Hematologic Malignancy Division, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Macrocytic* / genetics,  metabolism,  therapy
Antineoplastic Agents / therapeutic use
Chromosome Deletion*
Chromosomes, Human, Pair 5 / genetics,  metabolism
Clinical Trials as Topic
Gene Deletion
Humans
Thalidomide / analogs & derivatives,  therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 191732-72-6/lenalidomide; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Next Document:  Iron overload and allogeneic hematopoietic stem-cell transplantation.